Objectives. This study investigated the role of neuronal uptake of norepinephrine (uptake-l) in human heart failure as a local factor for altering concentrations of norepinephrine at the cardiac myocyte membranes.
force of contraction was decreased in relation to the degree of heart failure. In contrast, the potency of norepinephrine was increased in failing hearts (New York Heart Association functional class IV) in relation to the concentrations producing 50% of the maximal effect (ECso). The ECso values for isoproterenol, which is not a substrate for norepinephrine uptake-l, were reduced in myocardium in functional classes II to III and IV compared with those in nonfailing myocardium. The uptake inhibitors cocaine and desipramine (3/~mol/liter) potentiated the positive inotropic effects of norepinephrine in nonfailing myocardium (p < 0.05) but not in functional class IV myocardium. Radioligand binding experiments using the uptake inhibitor laydrogen-3 mazindol revealed a significant decrease by -30% in norepinephrine uptake-1 carrier density in functional classes II to III and IV myocardium versus nonfailing myocardium (p < 0.05).
Conclusions. In human heart failure, there is a presynaptic defect in the sympathetic nervous system, leading to reduced uptake-1 activity. This defect in the failing heart can be mimicked by the effects of uptake blocking agents, such as cocaine and desipramine, in the nonfailing heart only. Compromised norepinephrine uptake-1 in functional class IV cannot be further increased by cocaine and desipramine. The pathophysiologic consequences could be an increased synaptic concentration of norepinephrine predisposing to adenylyl cyclase desensitization.
(J Am Coil Cardiol 1995;25:146-53)
In failing human myocardium, the blunted cardiac responsiveness to beta-adrenergic stimulation is due to a reduction in betal-adrenoceptor density (1, 2) and an increase in Gi-alpha proteins (3) (4) (5) , which could be induced by an increased level of circulating catecholamines (6) (7) (8) , an increase in neuronal release of norepinephrine (9) or an impairment of neuronal uptake of norepinephrine, or a combination of these mechanisms. Cardiac neuronal uptake is the predominant mechanism for terminating the action of norepinephrine on betaadrenoceptors when catecholamines are released by sympathetic nerve terminals (10) . In patients with heart failure, data arguing against (11, 12) or in favor (13) of reduced myocardial norepinephrine uptake exist. However, direct experimental evidence in isolated failing human myocardium in favor of reduced norepinephrine uptake as well as its potential functional consequences is limited. The purpose of this study was to use functional and biochemical techniques to investigate the role of neuronal uptake of norepinephrine (uptake-i) in human heart failure as a local factor for altering concentrations of norepinephrine at the cardiac myocyte membranes. Studies were performed in electrically stimulated human ventricular cardiac preparations and isolated myocardial membranes. Tissue was obtained from patients who underwent mitral valve replacement or heart transplantation. For comparison, tissue from nonfailing donor hearts was studied.
Methods
Myocardial tissue. Myocardium from terminally failing human hearts was obtained from patients after cardieetomy during cardiac transplantation. The patients had dilated or ischemic cardiomyopathy and were in New York Heart Association functional class IV on the basis of clinical symptoms and signs as judged by the attending cardiologist shortly before operation. During mitral valve replacement, tissue from moderately failing hearts was obtained. All patients gave written informed consent before operation. Clinical details of the patients included in the study are shown in Table 1 . Flunitrazepam and pancuronium bromide with isoflurane were used for general anesthesia. Cardiac surgery was performed during CI = cardiac index; DCM = dilated cardiomyopathy; EF -ejection fraction; F -female; ICM = ischemic cardiomyopathy; LVEDP = left ventricular end-diastolic pressure; LVEDV -left ventricular end diastolic volume; M -male; MR = predominant mitral regurgitation; MS = predominant mitral stenosis; NYHA = New York Heart Association functional class (II to III -moderately failing myocardium, IV = severely failing myocardium); --= data not available.
cardiopulmonary bypass with cardioplegic arrest during hypothermia. The cardioplegic solution (modified Bretschneidcr solution) contained (in mmol/liter) NaCI 15, KC1 10, MgC12 4, histidine 180, tryptophan 2, mannitol 30 and potassium dihydrogen oxoglutarate 1. Nonfailing myocardium was obtained from five donors who were declared brain dead as a result of traumatic injury. These hearts could not be transplanted for technical reasons. Echocardiographic evaluation showed normal left ventricular function. Invasive hemodynamic measurements were not performed. None of the donors of the nonfailing hearts received sustained catecholamine treatment. However, bolus injections of catecholamines were documented in three patients during resuscitation after acute treatment of trauma. Thus, these hearts cannot be termed normal but only nonfailing. The reasons for not transplanting the hearts were fever, pericardial effusion or evidence for coronary heart disease. The use of human cardiac tissues was approved by the ethical committees of the Universities of Munich and Cologne.
Isolated cardiac preparation and measurement of force of contraction. Immediately after excision, papillary muscle strips were placed in ice-cold preaerated!.Tyrode solution and delivered to the laboratory within 10 min. The experiments were performed on isolated electrically driven muscle preparations. Muscle strips of uniform size with muscle fibers running approximately parallel to the length of the strips were dissected under microscopic control using scissors in aerated modified Tyrode solution (see composition later). Connective tissue was carefully trimmed away. The muscles were suspended in an organ bath (75 ml) maintained at 37°C and containing a modified Tyrode solution of the following composition (in retool/liter): NaC1 119.8, KC1 5.4, MgC12 1.05, CaC12 1.8, NaHCO 3 22.6, NaH2PO 4 0.42, glucose 5.0, ascorbic acid 0.28, ethylenediaminetetraacetic acid (EDTA) 0.05. The bathing solution was continuously aerated with 95% oxygen and 5% carbon dioxide. The muscles were stimulated by two platinum electrodes using field stimulation from a Grass $88 stimulator (frequency 1 Hz, impulse duration 5 ms, intensity 10% to 20% greater than threshold). Each muscle was stretched to the length at which force of contraction was maximal. The force at rest was kept constant throughout the experiment. The resultant tension was measured isometrically with an inductive force transducer (W. Fleck, Mainz, Germany) attached to a Gould recorder. Preparations were allowed to equilibrate for at least 90 min, with the bathing solution changed once after -45 min. Experimental details have been described elsewhere (3) .
Membrane preparation and radioligand binding experiments. Left ventricular myocardial tissue was chilled in 30 ml of ice-cold homogenization buffer (20 mmol/liter of tris(hydroxymethyl)aminomethane [Tris] hydrochloride, 4 mmol/liter of EDTA and 1 mmol/liter of dithiotheitol, pH 7.4). Connective tissue was trimmed away; myocardial tissue was minced with scissors; and membranes were homogenized with a motordriven glass-Teflon homogenizer for 1 min. The membrane preparation was then homogenized by hand with a glass-glass homogenizer. The homogenate was spun at 484 g (Beckman JA 20 rotor) for 15 min. The supernatant was filtered through four layers of gauze, diluted with an equal volume of potassium chloride (1 mol/liter) and stored on ice for 10 min. This suspension was centrifuged at 100,000 g for 30 min. The pellet was resuspended in 50 volumes of incubation buffer (50 mmol/liter of Tris He1, 120 mmol/liter of NaC1, 5 mmol/liter of KC1, pH 7.4) and homogenized for 1 rain with a glass-glass homogenizer. This suspension was recentrifuged at 100,000 g for 45 min. The final pellet was resuspended in incubation buffer and stored at -80°C. Storage did not alter the results. Protein was measured according to Lowry et al. (14) using bovine serum as standard. The assays were performed in a total volume of 250/zl. The incubation was carried out at 22°C for 60 min. These conditions allowed complete equilibration of the receptor with the radioligand. The reaction was terminated by rapid vacuum filtration through Whatman GF/C filters that were presoaked with 0.1% 3-([3-chelamidopryl]-dimethylamonio)-l-propansulfate (CHAPS) to reduce nonspecific binding. The filters were washed immediately three times with 6 ml of ice-cold incubation buffer to remove any unbound radioligand. All experiments were performed in triplicate. Radioactivity was determined in an LKB counter (Pharmacia LKB, Freiburg, Germany). Myocardial norepinephrine uptake carrier sites were studied using hydrogen-3 (H-3) mazindol (specific activity 24.7 Ci/mmol) as radiolabeled ligand (1 to 50 nmol/liter). Specific binding of H-3 mazindol was defined in the presence of desipramine (100/smol/liter).
Materials. (S)-(-)-Norepinephrine was from MerckSchuchardt (Hohenbrunn, Germany). Atropine sulfate and desipramine were purchased from Sigma Chemie GmbH (Deisenhofen, Germany). Cocaine solution was prepared in the pharmacy of the Klinikum GroBhadern (University of Munich). Hydrogen-3 mazindol (specific activity 24.7 Ci/ mmol) was from New England Nuclear-DuPont GmbH (Dreieich, Germany). All other compounds used were of analytic grade or the best grade commercially available. Only deionized and twice-distilled water was used throughout.
Statistical evaluation. All data are mean value _SEM. Statistical significance was estimated with the Student t test for unpaired observations and analysis of variance. The Scheff6 procedure for multiple comparisons was applied. A p value <0.05 was considered significant. The drug concentrations producing 50% of the maximal effect (ECs0) were graphically determined for each individual experiment.
Results
Effects of norepinephrine and isoproterenol. Figure 1 shows the positive inotropic effects of norepinephrine in isolated electrically driven papillary muscle strips from moderately (functional classes II to III) and severely (functional 
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Concentration of norepinephrine (/Jmol/I) Figure l. Concentration-response curves for the effect of norepinephrine (0.01 to 100 ~mol/liter) on isometric force of contraction in isolated electrically driven papillary muscle strips from nonfailing donor hearts (NF) and from patients undergoing mitral valve replacement (New York Heart Association [NYHA] functional classes II to III) or cardiac transplantation (functional class IV).
class IV) failing as well as nonfailing myocardium. Norepinephrine concentration dependently increased force of contraction in both groups. As expected, the positive inotropic effect of norepinephrine was reduced in papillary muscle strips from functional classes II to III and IV compared with that in nonfailing myocardium. To evaluate the potency of the betaadrenoceptor agonist, concentration-response curves for norepinephrine are shown in percent of the maximal effect in each preparation. Unexpectedly, the potency of norepinephrine to increase force of contraction was increased in functional classes II to III and IV myocardium compared with nonfailing myocardium (Fig. 1, bottom) . Correspondingly, the EC5o values were significantly lower in failing than in nonfailing myocardium ( Table 2 ). The increased potency of norepinephrine despite reduced maximal effects could either reflect more efficient coupling of the remaining beta-adrenoceptors or a reduced inactivation of norepinephrine by uptake-1 in failing myocardium. To address the latter, we compared the effects of norepinephrine with those of isoproterenol, which is not a substrate for uptake-1 (15, 16) , under same experimental con- . ECso values = concentration producing half-maximal effects (range); NYHA = New York Heart Association functional class (see Table 1 ).
ditions. The results are summarized in Figure 2 . As with norepinephrine, the maximal effects of isoproterenol were reduced in relation to the severity of heart failure (Fig. 2, top) . As shown in Figure 2 , bottom, the effects of isoproterenol were less potent in failing than in nonfailing myocardium, also in relation to the stage of the disease. Consistently, the ECso values were significantly higher in functional classes II to III and IV myocardium than in nonfailing myocardium. In summary, opposing results on the potency to increase force of contraction were obtained with isoproterenol, which is not a substrate for uptake-1 (15, 16) , and the physiologically occurring beta-adrenoceptor agonist norepinephrine, which is primarily inactivated by uptake-l, uptake into presynaptic stores (17) .
To further substantiate the evidence for a reduced uptake-1 in failing myocardium, experiments with the uptake-1 inhibitors desipramine and cocaine were performed. Some difference in the effect of these uptake-1 inhibitors on the concentration-response curve of norepinephrine in the different groups could be expected if there was an alteration in norepinephrine carrier. Figure 3 shows concentration-response curves for norepinephrine alone and in the presence of desipramine (3 /zmol/liter) or cocaine (3 /~mol/liter) in cardiac preparations from nonfailing myocardium. At 3/~mol/liter of desipramine or cocaine, force of contraction was reduced by -15% (not shown). Higher concentrations were not used because of the negative inotropic effects of the uptake-1 inhibitors. Cocaine and desipramine shifted the concentrationresponse curve of norcpinephrine to the left in nonfailing myocardium. The EC50 values were significantly reduced compared with those for norepinephrine alone (Table 2 ). Figure 4 summarizes the data in functional class IV myocardium. Neither desipramine nor cocaine affected the concentration- response curves in functional class IV myocardium. The ECso values of norepinephrine alone or in the presence of cocaine or desipramine in functional class IV myocardium were not significantly different from those in nonfailing myocardium in the presence of uptake-1 inhibitors. Thus, uptake-1 inhibition in nonfailing myocardium produced a situation similar to that in failing myocardium under control conditions. Norepinephrine uptake carrier sites. To quantitate norepinephrine uptake carrier sites directly, radioligand binding experiments were performed in functional classes II to III and IV myocardium and in nonfailing myocardium. Hydrogen-3 mazindol binding experiments were performed as described elsewhere (18) . Hydrogen-3 mazindol binding was strongly NaC1 dependent. Maximal specific binding was obtained in the presence of 120 mmol/liter of NaCI (not shown). Radioligand saturation binding experiments (in the presence of 120 mmol/ liter of NaC1) revealed concentration-dependent binding of the radioligand. Scatchard (19) analysis of the binding data showed monophasic binding with a specific binding of -30% at the dissociation constant (Ko) (not shown). The density of norepinephrine uptake carrier sites obtained with these techniques is shown in Figure 5 . There was a reduction by -30% in uptake sites in functional classes II to III and IV myocardium compared with nonfailing myocardium (p < 0.05). The absolute numbers and K o values are summarized in Table 3 .
Discussion
It is widely accepted that there is a general activation of the sympathetic nervous system in heart failure (6) (7) (8) 20) , which results in increased circulating norepinephrine levels at rest and during exercise (6) (7) (8) and correlates with the prognosis of patients with heart failure (6, 8) . In addition, Swedberg et al. (9) observed an increased release of norepinephrine from the myocardium of patients with heart failure compared with control subjects. The latter finding could result from increased activity of myocardial sympathetic neurons or impaired uptake of norepinephrine from the synaptic cleft, or both. Further evidence for local alteration of myocardial norepinephrine (i.e., uptake, release and synthesis) has been reported. There are reduced stores of myocardial norepinephrine (18, 21, 22) and a reduced myocardial turnover, including defects in catecholamine synthesis (23, 24) as well as reduced effects of the indirectly acting sympathomimetic drugs tyramine (25) and dopexamine (26) . Controversy exists about the involvement of norepinephrine uptake site mechanisms in heart failure. Rose et al. (13) reported a reduction in the rate of norepinephrine uptake and of norepinephrine release with a multiple indicator technique and reported a reduction in norepinephrine release from the myocardium of patients with dilated cardiomyopathy. However, Hasking et al. (12) provided evidence for unchanged norepinephrine uptake as judged from the kinetics of tritiated norepinephrine constantly applied to the myocardium of patients with heart failure. In agreement with the latter report, Meredith et al. (11) reported data on the cardiac outflow of the norepinephrine precursor dihydroxyphenylalanine, the intraneural metabolite of norepinephrine dihydroxyphenylglycol and of tritium-labeled norepinephrine. The latter report was in Table I ).
January 1995:146-53 NOREPINEPHRINE UPTAKE IN HEART FAILURE favor of an increased neuronal firing rate of sympathetic nerves in the presence of unchanged neuronal uptake. The discrepancies among available studies are apparently influenced by the different techniques used and the problem of differentiating between sympathetic activity and catecholamine uptake-1 in vivo.
Cardiac uptake-1 and contractility. To overcome the problems inherent in in vivo studies, we investigated the effects of norepinephrine compared with isoproterenol, which is not a substrate of uptake-l, uptake into presynaptic stores (15, 16) in isolated human myocardium in vitro. The efficiency of both beta-adrenoceptor agonists in increasing force of contraction was reduced in relation to severity of heart failure. These findings were reported earlier by several groups (1) (2) (3) 27) and might be related to postsynaptic alterations in beta-adrenergic signal transduction involving beta-adrenoceptor downregulation or uncoupling (1) (2) (3) 28) and increased levels of myocardial Gi-alpha (4-6). However, the opposite results were obtained with the two beta-adrenergic agonists when their potency was compared. As expected, and as previously reported (1), the potency of isoproterenol was observed to be reduced in failing myocardium. This could be the result of beta-adrenoceptor uncoupling and down-regulation (1, 2, 27, 28) . However, the potency of norepinephrine to increase force of contraction was increased in failing human myocardium.
This finding is compatible with the concept that exogenously applied norepinephrine is not inactivated because of a reduced capacity for norepinephrine uptake. If this were the case, one would expect that the concentration-response curve of norepinephrine would be affected differently by norepinephrine uptake-1 inhibitors, such as desipramine or cocaine. Indeed, cocaine and desipramine shifted the concentrationresponse curves of norepinephrine to the left in nonfailing myocardium but did not affect the effect of norepinephrine in failing human myocardium. Thus, another discrepancy exists between the in vivo data reported by Meredith et al. (11) and the in vitro data on isolated myocardium reported in the present study, some of which could be due to the fact that Meredith et al. (11) studied in vivo norepinephrine uptake in patients with moderate heart failure. Thus, norepinephrine uptake in the whole heart, including the vasculature and the arteries, is determined by using the techniques of Meredith et al. (11) . The experiments performed in the present study exclusively address alterations in norepinepbrine uptake in left ventricular myocardium. Conclusions drawn from these data cannot be uncritically extrapolated to other parts of the heart, such as the arteries or vasculature. Therefore, the different results indirectly indicate evidence of differences in norepinephrine uptake or even sympathetic innervation of different parts or components of the failing human heart. Finally, Meredith et al. (11) studied patients with hypertension or ischemic heart disease, or both, at the stage of moderate heart failure. In the present study, we evaluated myocardium from patients with terminal heart failure due to ischemic dilated cardiomyopathy as well as myocardial tissue from patients with mitral valve replacement. Therefore, the underlying cardiac disease could also have affected these differences.
Norepinephrine uptake carrier sites in isolated myocardial membranes. To substantiate functional findings with a biochemical technique, we labeled norepinephrine uptake-1 carrier sites with the radioligand H-3 mazindol. This compound has been reported to label catecholamine uptake carrier sites in the brain (18) . In the present study, we observed a significant reduction by -40% in H-3 mazindol binding sites in left ventricular particulate fractions from failing hearts compared with fractions from nonfailing hearts. In right heart failure in dogs caused by tricuspid valve avulsion, Liang et al. (29) reported a significant reduction by -50% of H-3 mazindol binding sites in the right but not left ventricle. The reduction of binding sites closely was correlated with the depressed norepinephrine uptake activity in the same hearts. These investigators concluded that local mechanisms could be related to the impairment of norepinephrine uptake confined to the right ventricle in their model. Norepinephrine uptake inhibitors failed to influence the concentration-response curve for norepinephrine, although the number of H-3 mazindol binding sites was reduced by 30%. Thus, a large portion of uptake-1 carriers in the present study of human heart might not participate in active norepinephrine inactivation.
Study limitations, A potential limitation of the radioligand binding experiments is the use of a high concentration of desipramine (100/zmol/liter) to determine nonspecific binding in experiments characterizing norepinephrine uptake carrier sites in human ventricular tissue. Thus it is possible that desipramine displaces H-3 mazindol binding from nonspecific binding sites. However, we could not reproduce the data of Liang et al. (29) , who reported numbers of H-3 mazindol binding sites similar to those herein by using 0.3 ~mol/liter of desipramine. Thus, H-3 mazindol binding to human myocardial membranes is more similar to binding sites in striatal membranes, where -30 to 100 /~mol/liter of desipramine is necessary to displace H-3 mazindol binding (18) . Such difficulties in quantifying norepinephrine uptake carrier sites by binding experiments emphasize the necessity of applying functional as well as biochemical methods to investigate reduced norepinephrine uptake-1 in failing myocardium.
Evidence for a reduction in norepinephrine uptake effects has been observed in the transplanted human heart. After transplantation, degeneration of the postganglionic ventricular nerve terminal has been observed in histologic (30) and immunohistologic (31) investigations. Consistently, as in the failing human heart (21, 22) , norepinephrine depletion occurs in the transplanted heart (26, 32) . Failing myocardium is also similar to transplanted heart myocardium with regard to uptake mechanisms. In heart transplant recipients the effect of epinephrine on myocardial force of contraction was observed to increase in vivo, whereas the effect of isoproterenol was unchanged (33) . Desipramine treatment in healthy volunteers enhanced the effect of epinephrine but was ineffective in heart transplant recipients (33) . To our knowledge these are the first
